Quarterly report pursuant to Section 13 or 15(d)

Segment Reporting (Tables)

v3.8.0.1
Segment Reporting (Tables)
 6 Months Ended
Dec. 31, 2017
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
These segments are components of the Company about which separate financial information is available and regularly evaluated by the chief operating decision maker in deciding how to allocate resources and in assessing performance.
 
Three Months Ended December 31, 2017 (in thousands)
 
iBio, Inc.
 
iBio CDMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
153
 
$
-
 
$
-
 
$
153
 
Revenues – intersegment
 
 
330
 
 
96
 
 
(426)
 
 
-
 
Research and development
 
 
676
 
 
482
 
 
(165)
 
 
993
 
General and administrative
 
 
1,221
 
 
1,694
 
 
(328)
 
 
2,587
 
Operating loss
 
 
(1,414)
 
 
(2,013)
 
 
-
 
 
(3,427)
 
Interest expense
 
 
-
 
 
(479)
 
 
-
 
 
(479)
 
Interest and other income
 
 
4
 
 
2
 
 
-
 
 
6
 
Consolidated net loss
 
 
(1,410)
 
 
(2,490)
 
 
-
 
 
(3,900)
 
Total assets
 
 
21,563
 
 
26,002
 
 
(12,725)
 
 
34,840
 
Fixed assets, net
 
 
7
 
 
25,282
 
 
-
 
 
25,289
 
Intangible assets, net
 
 
1,702
 
 
-
 
 
-
 
 
1,702
 
Depreciation expense
 
 
-
 
 
341
 
 
-
 
 
341
 
Amortization of intangible assets
 
 
84
 
 
-
 
 
-
 
 
84
 
 
Three Months Ended December 31, 2016 (in thousands)
 
iBio, Inc.
 
iBio CDMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
75
 
$
-
 
$
-
 
$
75
 
Revenues – intersegment
 
 
260
 
 
407
 
 
(667)
 
 
-
 
Research and development
 
 
1,016
 
 
447
 
 
(414)
 
 
1,049
 
General and administrative
 
 
1,241
 
 
1,363
 
 
(253)
 
 
2,351
 
Operating loss
 
 
(1,922)
 
 
(1,403)
 
 
-
 
 
(3,325)
 
Interest expense
 
 
-
 
 
(483)
 
 
-
 
 
(483)
 
Interest and other income
 
 
9
 
 
7
 
 
-
 
 
16
 
Consolidated net loss
 
 
(1,913)
 
 
(1,879)
 
 
-
 
 
(3,792)
 
Total assets
 
 
9,870
 
 
34,333
 
 
(15)
 
 
44,188
 
Fixed assets, net
 
 
7
 
 
25,446
 
 
-
 
 
25,453
 
Intangible assets, net
 
 
1,960
 
 
-
 
 
-
 
 
1,960
 
Depreciation expense
 
 
1
 
 
325
 
 
-
 
 
326
 
Amortization of intangible assets
 
 
88
 
 
-
 
 
-
 
 
88
 
 
Six Months Ended December 31, 2017 (in thousands)
 
iBio, Inc.
 
iBio CDMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
237
 
$
38
 
$
-
 
$
275
 
Revenues – intersegment
 
 
631
 
 
306
 
 
(937)
 
 
-
 
Research and development
 
 
1,294
 
 
966
 
 
(282)
 
 
1,978
 
General and administrative
 
 
2,320
 
 
3,392
 
 
(627)
 
 
5,085
 
Operating loss
 
 
(2,746)
 
 
(4,042)
 
 
-
 
 
(6,788)
 
Interest expense
 
 
-
 
 
(959)
 
 
-
 
 
(959)
 
Interest and other income
 
 
16
 
 
4
 
 
-
 
 
20
 
Consolidated net loss
 
 
(2,730)
 
 
(4,997)
 
 
-
 
 
(7,727)
 
Total assets
 
 
21,563
 
 
26,002
 
 
(12,725)
 
 
34,840
 
Fixed assets, net
 
 
7
 
 
25,282
 
 
-
 
 
25,289
 
Intangible assets, net
 
 
1,702
 
 
-
 
 
-
 
 
1,702
 
Depreciation expense
 
 
1
 
 
678
 
 
-
 
 
679
 
Amortization of intangible assets
 
 
169
 
 
-
 
 
-
 
 
169
 
 
Six Months Ended December 31, 2016 (in thousands)
 
iBio, Inc.
 
iBio CDMO
 
Eliminations
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues - external customers
 
$
161
 
$
49
 
$
-
 
$
210
 
Revenues – intersegment
 
 
412
 
 
589
 
 
(1,001)
 
 
-
 
Research and development
 
 
1,700
 
 
768
 
 
(599)
 
 
1,869
 
General and administrative
 
 
2,588
 
 
2,634
 
 
(402)
 
 
4,820
 
Operating loss
 
 
(3,715)
 
 
(2,764)
 
 
-
 
 
(6,479)
 
Interest expense
 
 
-
 
 
(966)
 
 
-
 
 
(966)
 
Interest and other income
 
 
27
 
 
14
 
 
-
 
 
41
 
Consolidated net loss
 
 
(3,688)
 
 
(3,716)
 
 
-
 
 
(7,404)
 
Total assets
 
 
9,870
 
 
34,333
 
 
(15)
 
 
44,188
 
Fixed assets, net
 
 
7
 
 
25,446
 
 
-
 
 
25,453
 
Intangible assets, net
 
 
1,960
 
 
-
 
 
-
 
 
1,960
 
Depreciation expense
 
 
2
 
 
648
 
 
-
 
 
650
 
Amortization of intangible assets
 
 
176
 
 
-
 
 
-
 
 
176